Results 221 to 230 of about 863,493 (265)

Antibody Therapies in Cancer

2016
Antibody-based immunotherapy has become a standard treatment for a variety of cancers. Many well-developed antibodies disrupt signaling of various growth factor receptors for the treatment of a number of cancers by targeting surface antigens expressed on tumor cells. In recent years, a new family of antibodies is currently emerging in the clinic, which
Shengdian, Wang, Mingming, Jia
openaire   +2 more sources

Monoclonal antibody therapy

2001
Publisher Summary Monoclonal antibody therapy (MAT) makes use of all the major features of the immune response. It involves vaccination/ immunization, albeit in experimental animals, to induce the desired specific immune response. It exploits the high specificity, selectivity, and affinity of the antibody complementarity-determining regions (CDRs ...
J W, Park, J, Smolen
openaire   +2 more sources

Cancer therapy with antibodies

Nature Reviews Cancer
The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage to normal cells. Targeted therapy has been developed to meet that challenge, showing a substantially increased therapeutic index compared with conventional cancer therapies.
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M. Wright, Sandra B. Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou   +9 more
openaire   +2 more sources

Monoclonal Antibodies in Cancer Therapy

Current Medicinal Chemistry-Anti-Cancer Agents, 2004
The recent approval of cetuximab and bevacizumab by FDA for the treatment of metastatic colorectal cancer witnesses the investments of biotech companies in the development of monoclonal antibodies (Mabs) as cancer therapeutics. Several analyses point to the growth of the market for these drugs, and forecast an even higher expansion of sales following ...
openaire   +3 more sources

Tumour Therapy with Radiolabelled Antibodies

BioDrugs, 1998
The promise of radiolabelled immunoglobulin therapy (RIT) for selective, patient friendly, cancer treatment has not yet been fulfilled. Only patients with haematological malignancies show sizable response rates after RIT. With solid tumours, intravenous administration of radiolabelled antibodies does not provide sufficient tumour targeting.
H M, Vriesendorp, S M, Quadri, P E, Borchardt   +2 more
openaire   +2 more sources

Monoclonal antibody therapy for lymphoma

Blood Reviews, 2003
Monoclonal antibodies are an exciting advance in the treatment of lymphoma. They are safe and well-tolerated, and exhibit little cross-resistance with conventional chemotherapeutic agents. In indolent lymphomas, antibody therapy has shown useful response rates, both as first-line therapy and in relapsed disease.
Peter, Campbell, Robert, Marcus
openaire   +2 more sources

Signaling antibodies in cancer therapy

Current Opinion in Immunology, 1999
Over the past 10-15 years, genetic engineering of monoclonal antibodies has greatly improved their utility in humans and in particular their ability to recruit immunological effectors such as natural killer cells and macrophages. Clinical results now confirm that these new reagents, when directed at the appropriate tumor markers (e.g.
M S, Cragg, R R, French, M J, Glennie
openaire   +2 more sources

Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

Ca-A Cancer Journal for Clinicians, 2022
Shanu Modi, Cortes J, Roberto Carmagnani Pestana   +2 more
exaly  

Advances in antibody-based therapy in oncology

Nature Cancer, 2023
Lutz Jermutus, Daniel Christ, Puja Sapra   +2 more
exaly  

Antitumor antibodies for therapy

International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1989
I, Hellström, K E, Hellström
openaire   +2 more sources